The Evaluation of Safety and Tolerance of Commercially Available Naltrexone Administered Daily - Assessment for CBRN Operations — TEST CANADA

Opioid Intoxication Clinical Trial

Official title:
The Evaluation of Safety and Tolerance of Commercially Available Naltrexone Administered Daily - Assessment for CBRN Operations

Status Completed

Clinical Trial Summary

The objective of this study is to evaluate the tolerance and safety of naltrexone while performing military specific tasks, and to assess plasma concentrations following naltrexone, administered orally at 50 mg per day for 7 days. The physical and mental/cognitive performance assessments will be conducted at various times prior, during and following drug administration. Daily blood draws will also be taken to assess blood levels of naltrexone and active metabolites for correlation to performance parameters associated with the Military Skill & Tasked Based Fitness Test.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Opioid Intoxication

Clinical Trial Details

NCT number	NCT03879460
Study type	Interventional
Source	Canadian Department of National Defense
Contact
Status	Completed
Phase	Phase 1
Start date	March 18, 2019
Completion date	March 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03368794` - Naloxone to TReatment Entry in the Emergency Setting	N/A
Completed	`NCT04047550` - Respiratory Control and Narcotic Effects
Not yet recruiting	`NCT03394911` - Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction	Phase 3